Know Cancer

forgot password

Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC

Phase 2
18 Years
Open (Enrolling)

Thank you

Trial Information

Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC

This is an open-label, outpatient Phase II, prospective, randomized, single-center, clinical
trial. Up to 14 patients with a diagnosis of unresectable stage III or stage IV melanoma.

All patients will undergo leukapheresis to collect PBMC.

All patients will receive Cyclophosphamide 350 mg/m2 dl-3 and Fludarabine 20 mg/m2 dl-3.

Following chemotherapy to induce lymphopenia, patients will be re-infused with PDMC as

Autologous PBMC re-infusion (Cohort A) Autologous, CD25-depleted PBMC re-infusion (Cohort B)

Following PBMC re-infusion, all patients will receive subcutaneous GM-CSF Infusion (50
micrograms/24 hrs) continuously for 6 days.

All patients will then receive 4 booster vaccinations as follows:

Intradermal injection of autologous tumor cells in the lower abdomen to deliver a total dose
of at least 2x107 cells administered week 3, week 5, week 9 and week 13. Subcutaneous GM-CSF
Infusion (50 micrograms/24 hrs) adjacent to the vaccine site begins at time of vaccination
(week 3, 5, 9 and 13) and continues for 6 days.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed malignant melanoma that
is unresectable stage III or stage IV. Measurable disease is not required.

- Patients must have failed, refused, or not been eligible to receive at least one
standard therapy regimen for metastatic disease.

- Easily harvested metastatic tumor cells e.g., skin or lymph node metastases or a
planned surgery to remove tumor. Patients undergoing resection of a solitary brain
metastasis are eligible if their resected lesion contains an adequate number of tumor
cells. A minimum 2 cm x 2 cm x 2 cm lesion will be required for study eligibility.

- Sufficient viable tumor cells harvested to generate the vaccine. The tumor collected
must contain greater than 1.6 x 108 viable tumor cells or a cell line generated from
autologous tumor must provide greater than 1.6 x 108 viable tumor cells.

- Patients may have received prior chemotherapy and/or immunotherapy. Prior radiation
therapy is acceptable but previously radiated sites may not be used for tumor
collection for vaccine preparation.

- Life expectancy of greater than or = 3 months.

- ECOG performance status <2 (Karnofsky >60%; see Appendix A).

- Patients must have normal organ and marrow function at the time of enrollment as
defined in the protocol.

- Patients must be seronegative for HIV, Hepatitis B surface antigen and Hepatitis C

- If patients have had recent surgery, they must have recovered from the effects of
that surgery in the opinion of the investigator.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Patients who have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or
mitomycin C).

- Radiation therapy within 2 weeks. Prior radiation must have been to less 30% of the
bone marrow and patient has recovered from all side effects, in the opinion of the

- Patients may not be receiving any other investigational agents.

- Steroid therapy, other than replacement steroids and inhaled steroids. Patients who
might require systemic corticosteroids other than replacement steroids during the
next three months are not eligible for this study.

- Patients with known brain metastases unless treated with radiation therapy and/or
surgery and shown to be stable > 1 month.

- Autoimmune disease requiring treatment, with the exception of controlled autoimmune
thyroiditis or vitiligo.

- Pregnant or nursing women are excluded from this study because fludarabine and
cyclophosphamide have potential teratogenic effects. It is not known whether
fludarabine is excreted in breast milk but the package insert cautions that it might
and recommends against breastfeeding if the mother is treated with fludarabine.

- Uncontrolled intercurrent illness which, in the opinion of the investigator, may
increase the risks associated with study participation or interfere with the
interpretation of the results..

- Any other medical illness or psychiatric condition/social situations that in the
opinion of the principal investigator would compromise the patients ability to
tolerate this treatment or would limit compliance with study requirements.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Immunologic effects (changes in the number of tumor specific T cells)

Outcome Description:

The absolute number and frequency of tumor specific T cells will be measured at days 7, 21, 35, 64, 91, and day 119.

Outcome Time Frame:

Up to day 119

Safety Issue:



United States: Food and Drug Administration

Study ID:

PHS IRB 06-55



Start Date:

July 2009

Completion Date:

December 2012

Related Keywords:

  • Melanoma
  • melanoma
  • unresectable stage III or IV melanoma
  • Melanoma



Providence Portland Medical Center Portland, Oregon  97213-3635